Spots Global Cancer Trial Database for Study of AFP464 +/- Faslodex in ER + Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AFP464 +/- Faslodex in ER + Breast Cancer
Official Title: A Randomized Phase II Study of AFP464 +/- Faslodex in ER Positive Breast Cancer Patients Who Had Progressed on Aromatase Inhibitor (AI) Therapy
Study ID: NCT01233947
Conditions
Study Description
Brief Summary: AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
Detailed Description: This is a randomized, open-label study. Patients will be randomized in a 1:1 ratio to single arm AFP464, or AFP464+Faslodex. Patients will be treated until disease progression is noted.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Contact Details
Name: Joanne L. Blume, M.D.
Affiliation: Texas Oncology-Baylor Charles A. Sammons Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
